BI-1181181 clinical trials
Also written BI 1181181.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses BI-1181181 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BI 1181181
- 2
Studies by the year they started
4 studies that test it; most in 2014 (3)
| Year | Studies |
|---|---|
| 2014 | 3 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses BI-1181181 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Multiple Rising Dose of BI 1181181 Given Orally in Young Healthy Male and Elderly Healthy Male/Female VolunteersTerminatedPhase 1Boehringer IngelheimNCT02254161Written as BI 1181181 healthy elderly
- Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and DigoxinWithdrawnPhase 1Boehringer IngelheimNCT02345304Written as BI 1181181
- Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181CompletedPhase 1Boehringer IngelheimNCT02044406Written as BI 1181181
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02106247Written as BI 1181181 high dose